Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial von Giugliano, RP, Pedersen, TR, Park, J-G, De Ferrari, GM, Gaciong, ZA, Ceska, R, Toth, K, Gouni-Berthold, I, Lopez-Miranda, J, Schiele, F, Mach, F, Ott, BR, Kanevsky, E, Pineda, AL, Somaratne, R, Wasserman, SM, Keech, AC, Sever, PS, Sabatine, MS, FOURIER Investigators

Volltext

Effect of the PCSK9 inhibitor evolocumab on total cardiovascular events in patients with cardiovascular disease: A prespecified analysis from the FOURIER Trial von Murphy, SA, Pedersen, TR, Gaciong, ZA, Ceska, R, Ezhov, MV, Connolly, DL, Jukema, JW, Toth, K, Tikkanen, MJ, Im, K, Wiviott, SD, Kurtz, CE, Honarpour, N, Giugliano, RP, Keech, AC, Sever, PS, Sabatine, MS

Volltext

ACE genotype and progression of IgA nephropathy von Gaciong, ZbigniewA, Religa, Piotr, Placha, Grzegorz, Rell, Krzysztof, Paczek, Leszek, Khan, I.H., MacLeod, A.M., Ringrose, T.R., Thomas, T., Wilkinson, R., Jardine, Alan, Harden, Paul, Boulton-Jones, Michael, Connell, JohnM.C., Fukushima, Tatsuo, Nomura, Shinsuke, Kawai, Shinichiro, Osawa, Gengo, Roy-Chaudhury, Prabir

Volltext